Answers are grounded in this paper and cite their sources.
Purpose: Corneal endothelial dysfunction causes irreversible blindness, yet treatment remains limited by donor tissue shortage. This study aimed to generate induced corneal endothelial-like cells (iCEnCs) from mouse neural crest cells (NCCs) via TGF-β inhibition. Methods: NCCs were isolated from Wnt1-Cre; Rosa26-LSL-tdTomato mice by fluorescence-activated cell sorting. NCCs were treated with the TGF-β inhibitor SB431542 to induce differentiation into iCEnCs. The CEnC-like phenotype was characterized by immunofluorescence, functional assays, and bulk RNA sequencing in comparison with mouse NCCs and CEnCs. Therapeutic efficacy was assessed by transplanting iCEnCs into a rabbit model of corneal endothelial dysfunction. Results: SB431542 efficiently directed NCCs to differentiate into polygonal, cobblestone-like iCEnCs expressing CEnC markers (ZO-1, Na⁺/K⁺-ATPase, AQP1, Laminin). Approximately 35% of iCEnCs at P5 remained Ki67-positive, indicating maintained proliferative activity. These cells also achieved near-complete wound closure within 24 hours. Transcriptomic profiling showed that iCEnCs resembled primary corneal endothelial cells (pCEnCs) and were distinct from NCCs. After transplantation, iCEnCs formed a confluent endothelial-like monolayer, normalized central corneal thickness by day 21, and restored corneal transparency by day 35. Conclusions: TGF-β signaling inhibition enables efficient differentiation of mouse NCCs into corneal endothelial-like cells with functional characteristics, maintained proliferative activity, and in vivo therapeutic efficacy. This strategy provides a potential scalable, donor-independent cell source for the development of cell-based therapies for corneal endothelial diseases.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: